USE OF ESTRADIOL VALERATE OR ESTRADIOL COMBINED WITH DIENOGEST FOR THE ORAL THERAPY OF DYSFUNCTIONAL UTERINE BLEEDING IN THE FORM OF ORAL CONTRACEPTIVES

摘要

The present invention provides for the preparation of a multi-stage combination formulation for oral treatment of dysfunctional uterine bleeding in the form of an oral contraceptive, 17α-cyanomethyl-17β-hydroxyestra-4,9-dien-3-one (dieno Guest) in combination with estradiol valeralate or estradiol. This combination of estradiol valerate or estradiol and dienoguest is a first step comprising 2 mg of estradiol or less than 3 mg of estradiol daily dosage, 2 mg of estradiol valerate Or a first set comprising 5 daily doses of a combination of less than 2 mg of estradiol and 2 mg of dienoguest and 2 mg of estradiol valerate or less than 2 mg of estradiol and 3 mg of die Combination with noguest A second stage consisting of two sets of daily doses comprising a second stage comprising 17 daily doses, 1 mg of estradiol valerate or less than 2 mg of estradiol 1 A third step comprising two daily doses, and an additional step comprising two pharmaceutically harmless placebo daily doses. The total number of daily doses of the multi-stage combination and pharmaceutically harmless placebo corresponds to 28 days. The coverage period includes one or more menstrual cycles, depending on the individual woman's wishes for contraception.